Corcept Therapeutics Incorporated(CORT)Earnings, Financials & Key Ratios

CORT•NASDAQ

$51.05

$5.48B mkt cap·62.3× P/E·Price updated May 7, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryCommercial Rare Disease Biopharma

AboutCorcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.Show more

Revenue$761M+12.8%
EBITDA$47M-66.2%
Net Income$100M-28.7%
EPS (Diluted)0.82-33.3%
Gross Margin98.3%
EBITDA Margin6.13%-70.1%
Operating Margin5.88%-71.0%
Net Margin13.09%-36.8%
ROE15.01%-36.3%
ROIC6.15%-72.1%
Debt/Equity0.01-7.6%

Technical→

CORT Key Insights

Corcept Therapeutics Incorporated (CORT) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Company is almost debt free
✓FCF machine: 18.6% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 16.6%
✓Good 3Y average ROE of 19.9%
✓Healthy 5Y average net margin of 22.4%

✗Weaknesses

✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

CORT Price & Volume

Corcept Therapeutics Incorporated (CORT) stock price & volume — 10-year historical chart

Loading chart...

CORT Growth Metrics

Corcept Therapeutics Incorporated (CORT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years31.23%

5 Years16.56%

3 Years23.74%

TTM12.2%

Profit CAGR

10 Years-

5 Years-1.23%

3 Years-0.58%

TTM-64.01%

EPS CAGR

10 Years-

5 Years-0.72%

3 Years-1.95%

TTM-69.83%

Return on Capital

10 Years27.78%

5 Years20.59%

3 Years16.64%

Last Year6.54%

CORT Recent Earnings

Corcept Therapeutics Incorporated (CORT) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 7/12 qtrs (58%)●Beat Revenue 4/12 qtrs (33%)

Q2 2026Latest

Apr 30, 2026

EPS

$0.30

Est $0.11

-176.5%

Revenue

$165M

Est $186M

-11.3%

Q1 2026

Feb 24, 2026

EPS

$0.20

Est $0.33

-39.4%

Revenue

$202M

Est $255M

-20.7%

Q4 2025

Nov 4, 2025

EPS

$0.16

Est $0.18

-11.1%

Revenue

$208M

Est $255M

-18.7%

Q3 2025

Jul 31, 2025

EPS

$0.29

Est $0.23

+26.1%

Revenue

$194M

Est $245M

-20.5%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	Apr 30, 2026	$0.30vs $0.11-176.5%	$165Mvs $186M-11.3%
Q1 2026	Feb 24, 2026	$0.20vs $0.33-39.4%	$202Mvs $255M-20.7%
Q4 2025	Nov 4, 2025	$0.16vs $0.18-11.1%	$208Mvs $255M-18.7%
Q3 2025	Jul 31, 2025	$0.29vs $0.23+26.1%	$194Mvs $245M-20.5%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
INVAInnoviva, Inc.Direct Competitor	1.93B	22.80	6.91	18.52%	118.91%	46.47%	0.23
HRMYHarmony Biosciences Holdings, Inc.Direct Competitor	1.82B	31.42	11.59	21.51%	16.2%	17.19%	0.28
SUPNSupernus Pharmaceuticals, Inc.Direct Competitor	3.01B	52.28	-76.88	8.63%	-3.74%	-2.73%	0.04
PRGOPerrigo Company plcDirect Competitor	1.61B	11.72	-1.14	-2.75%	-43.5%	-50.65%	1.35
PAHCPhibro Animal Health CorporationDirect Competitor	1.75B	43.16	36.27	27.37%	6.29%	30.81%	2.67
VNDAVanda Pharmaceuticals Inc.Direct Competitor	377.7M	6.39	-1.71	8.72%	-109.99%	-61.41%	0.04
OSUROraSure Technologies, Inc.Direct Competitor	225.25M	3.13	-3.33	-38.1%	-61.93%	-15.09%	0.04
AXSMAxsome Therapeutics, Inc.Product Competitor	11.33B	220.10	-59.81	65.55%	-26.59%	-260.01%	2.73

Compare CORT vs Peers

Corcept Therapeutics Incorporated (CORT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs INVA

Most directly comparable listed peer for CORT.

Scale Benchmark

vs CVS

Larger-name benchmark to compare CORT against a more recognizable public peer.

Peer Set

Compare Top 5

vs INVA, HRMY, SUPN, PRGO

CORT Income Statement

Corcept Therapeutics Incorporated (CORT) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Sales/Revenue	159.2M	251.25M	306.49M	353.87M	365.98M	401.86M	482.38M	675.04M	761.41M	769.1M
Revenue Growth %	95.77%	57.82%	21.99%	15.46%	3.42%	9.8%	20.04%	39.94%	12.79%	12.2%
Cost of Goods Sold	3.55M	5.21M	5.5M	5.58M	5.28M	5.38M	6.48M	10.88M	12.98M	13.46M
COGS % of Revenue	2.23%	2.08%	1.8%	1.58%	1.44%	1.34%	1.34%	1.61%	1.7%	-
Gross Profit	155.65M▲ 0%	246.03M▲ 58.1%	300.98M▲ 22.3%	348.29M▲ 15.7%	360.7M▲ 3.6%	396.47M▲ 9.9%	475.89M▲ 20.0%	664.16M▲ 39.6%	748.43M▲ 12.7%	755.64M▲ 0%
Gross Margin %	97.77%	97.92%	98.2%	98.42%	98.56%	98.66%	98.66%	98.39%	98.3%	98.25%
Gross Profit Growth %	96.37%	58.07%	22.33%	15.72%	3.56%	9.92%	20.03%	39.56%	12.69%	-
Operating Expenses	102.79M	156.54M	189.38M	220.09M	236.22M	283.84M	368.61M	527.21M	703.63M	763.86M
OpEx % of Revenue	64.57%	62.3%	61.79%	62.19%	64.54%	70.63%	76.42%	78.1%	92.41%	-
Selling, General & Admin	62.42M	81.29M	100.36M	105.33M	122.36M	152.85M	184.26M	280.32M	448.73M	503.42M
SG&A % of Revenue	39.21%	32.35%	32.75%	29.76%	33.43%	38.04%	38.2%	41.53%	58.93%	-
Research & Development	40.38M	75.25M	89.02M	114.76M	113.86M	130.99M	184.35M	246.89M	254.91M	260.44M
R&D % of Revenue	25.36%	29.95%	29.04%	32.43%	31.11%	32.6%	38.22%	36.57%	33.48%	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	1
Operating Income	52.85M▲ 0%	89.5M▲ 69.3%	111.61M▲ 24.7%	128.2M▲ 14.9%	124.48M▼ 2.9%	112.63M▼ 9.5%	107.28M▼ 4.8%	136.95M▲ 27.7%	44.8M▼ 67.3%	-8.22M▲ 0%
Operating Margin %	33.2%	35.62%	36.41%	36.23%	34.01%	28.03%	22.24%	20.29%	5.88%	-1.07%
Operating Income Growth %	419.26%	69.32%	24.7%	14.87%	-2.91%	-9.51%	-4.75%	27.66%	-67.29%	-
EBITDA	52.96M	89.73M	113.78M	130.44M	127.54M	113.89M	108.32M	138.29M	46.69M	-6.79M
EBITDA Margin %	33.27%	35.71%	37.12%	36.86%	34.85%	28.34%	22.46%	20.49%	6.13%	-0.88%
EBITDA Growth %	415.89%	69.43%	26.8%	14.64%	-2.22%	-10.7%	-4.89%	27.66%	-66.24%	-106.03%
D&A (Non-Cash Add-back)	106K	236K	2.17M	2.24M	3.07M	1.26M	1.04M	1.34M	1.89M	1.43M
EBIT	52.85M	89.5M	111.61M	128.2M	125.01M	112.63M	107.28M	136.95M	44.8M	-8.22M
Net Interest Income	-49K	2.66M	5.07M	3.4M	529K	3.56M	17.27M	24.54M	0	0
Interest Income	0	2.66M	5.07M	3.4M	529K	3.56M	17.27M	24.54M	0	0
Interest Expense	49K	0	0	0	0	0	0	0	0	0
Other Income/Expense	-49K	2.66M	5.07M	3.4M	529K	3.56M	17.27M	24.54M	21.67M	20.35M
Pretax Income	52.81M▲ 0%	92.15M▲ 74.5%	116.68M▲ 26.6%	131.6M▲ 12.8%	125.01M▼ 5.0%	116.19M▼ 7.1%	124.56M▲ 7.2%	161.49M▲ 29.7%	66.46M▼ 58.8%	12.13M▲ 0%
Pretax Margin %	33.17%	36.68%	38.07%	37.19%	34.16%	28.91%	25.82%	23.92%	8.73%	1.58%
Income Tax	-76.32M	16.74M	22.5M	25.59M	12.49M	14.77M	18.42M	20.28M	-33.19M	-35.77M
Effective Tax Rate %	-144.52%	18.17%	19.28%	19.45%	9.99%	12.71%	14.79%	12.56%	-49.94%	-294.91%
Net Income	129.12M▲ 0%	75.41M▼ 41.6%	94.18M▲ 24.9%	106.01M▲ 12.6%	112.51M▲ 6.1%	101.42M▼ 9.9%	106.14M▲ 4.7%	139.73M▲ 31.6%	99.65M▼ 28.7%	47.9M▲ 0%
Net Margin %	81.11%	30.01%	30.73%	29.96%	30.74%	25.24%	22%	20.7%	13.09%	6.23%
Net Income Growth %	1486.27%	-41.6%	24.89%	12.56%	6.13%	-9.86%	4.66%	31.65%	-28.68%	-64.01%
Net Income (Continuing)	129.12M	75.41M	94.18M	106.01M	112.51M	101.42M	106.14M	141.21M	99.65M	47.9M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)	1.04▲ 0%	0.60▼ 42.3%	0.77▲ 28.3%	0.85▲ 10.4%	0.89▲ 4.7%	0.87▼ 2.2%	0.94▲ 8.0%	1.23▲ 30.9%	0.82▼ 33.3%	0.46▲ 0%
EPS Growth %	1385.71%	-42.31%	28.33%	10.39%	4.71%	-2.25%	8.05%	30.85%	-33.33%	-69.83%
EPS (Basic)	1.14	0.60	0.82	0.92	0.97	0.95	1.02	1.35	0.95	-
Diluted Shares Outstanding	124.52M	126.69M	122.57M	124.19M	125.96M	115.97M	111.74M	113.48M	119.99M	104.44M
Basic Shares Outstanding	113.53M	125.68M	114.35M	115.41M	115.65M	106.79M	103.56M	103.23M	103.86M	104.44M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

CORT Balance Sheet

Corcept Therapeutics Incorporated (CORT) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Total Current Assets	140.6M	240.59M	307.36M	478.5M	266.46M	499.25M	458.64M	471.6M	485.46M	426.03M
Cash & Short-Term Investments	104.03M	206.76M	275.96M	440.7M	223.53M	431.67M	368.22M	383.33M	372.15M	338.18M
Cash Only	104.03M	206.76M	31.27M	76.19M	77.62M	66.33M	135.55M	127.67M	120.5M	108.74M
Short-Term Investments	0	0	244.69M	364.51M	145.92M	365.34M	232.67M	255.67M	251.66M	229.45M
Accounts Receivable	28.2M	17.59M	19.93M	26.2M	29.02M	46.86M	56.82M	58.08M	59.79M	39.07M
Days Sales Outstanding	64.64	25.55	23.73	27.02	28.95	42.56	43	31.4	28.66	28.6
Inventory	8.38M	16.24M	5.42M	4.91M	4.99M	6.1M	7.73M	12.41M	12.87M	12.89M
Days Inventory Outstanding	860.23	1.14K	359.69	321.06	344.75	413.46	435.34	416.32	361.93	341.64
Other Current Assets	2.67M	7.74M	6.04M	6.7M	8.91M	14.62M	25.86M	8.29M	40.66M	35.89M
Total Non-Current Assets	79.94M	71.1M	104.95M	93.23M	157.29M	84.18M	162.88M	368.95M	351.19M	388.85M
Property, Plant & Equipment	518K	655K	4.5M	4.18M	1.52M	1.78M	315K	8.01M	6.47M	10.37M
Fixed Asset Turnover	307.34x	383.58x	68.17x	84.58x	241.41x	226.27x	1531.35x	84.24x	117.63x	99.17x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	15.28M	0	39.35M	36.2M	112.28M	4.95M	57.18M	219.83M	0	275.33M
Other Non-Current Assets	3.24M	7.79M	15.43M	21.25M	16.05M	15.99M	14.79M	10.19M	176.52M	409.78M
Total Assets	220.54M▲ 0%	311.69M▲ 41.3%	412.31M▲ 32.3%	571.73M▲ 38.7%	423.76M▼ 25.9%	583.43M▲ 37.7%	621.52M▲ 6.5%	840.55M▲ 35.2%	836.65M▼ 0.5%	814.88M▲ 0%
Asset Turnover	0.72x	0.81x	0.74x	0.62x	0.86x	0.69x	0.78x	0.80x	0.91x	0.94x
Asset Growth %	220.77%	41.33%	32.28%	38.66%	-25.88%	37.68%	6.53%	35.24%	-0.46%	13.02%
Total Current Liabilities	29.57M	35.81M	38.84M	47.49M	47.54M	72.49M	104.5M	140.77M	166.09M	149.19M
Accounts Payable	8.58M	8.27M	7.54M	10.55M	6.91M	11.98M	17.4M	15.38M	40.44M	33.31M
Days Payables Outstanding	881.07	578.54	499.82	690.11	477.45	811.74	979.72	515.74	1.14K	893.18
Short-Term Debt	0	0	1.56M	2.05M	526K	1.14M	151K	829K	1.08M	1.63M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	12.42M	17.89M	16.94M	24.75M	26.25M	43.77M	59.69M	82.65M	124.56M	114.25M
Current Ratio	4.75x	6.72x	7.91x	10.07x	5.60x	6.89x	4.39x	3.35x	2.92x	2.92x
Quick Ratio	4.47x	6.26x	7.77x	9.97x	5.50x	6.80x	4.31x	3.26x	2.85x	2.85x
Cash Conversion Cycle	43.8	583.79	-116.39	-342.03	-103.75	-355.72	-501.38	-68.02	-746.96	-522.94
Total Non-Current Liabilities	0	239K	2.29M	899K	409K	9.1M	10.31M	20.19M	22.76M	27.71M
Long-Term Debt	0	0	0	0	0	0	0	0	5.02M	8.01M
Capital Lease Obligations	0	0	1.9M	501K	0	0	0	6.11M	0	10.9M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	239K	386K	398K	409K	9.1M	10.31M	14.08M	17.74M	67.25M
Total Liabilities	29.57M	35.81M	41.13M	48.39M	47.95M	81.59M	114.81M	160.96M	188.85M	176.89M
Total Debt	0	0	3.46M	2.55M	526K	1.14M	151K	6.94M	6.11M	9.64M
Net Debt	-104.03M	-206.76M	-27.81M	-73.64M	-77.09M	-65.19M	-135.4M	-120.73M	-114.39M	-99.1M
Debt / Equity	-	-	0.01x	0.00x	0.00x	0.00x	0.00x	0.01x	0.01x	0.01x
Debt / EBITDA	-	-	0.03x	0.02x	0.00x	0.01x	0.00x	0.05x	0.13x	-1.42x
Net Debt / EBITDA	-1.96x	-2.30x	-0.24x	-0.56x	-0.60x	-0.57x	-1.25x	-0.87x	-2.45x	-2.45x
Interest Coverage	1078.67x	-	-	-	-	-	-	-	-	-
Total Equity	190.97M▲ 0%	275.88M▲ 44.5%	371.18M▲ 34.5%	523.34M▲ 41.0%	375.81M▼ 28.2%	501.84M▲ 33.5%	506.7M▲ 1.0%	679.59M▲ 34.1%	647.8M▼ 4.7%	637.99M▲ 0%
Equity Growth %	361.51%	44.46%	34.54%	40.99%	-28.19%	33.54%	0.97%	34.12%	-4.68%	-5.76%
Book Value per Share	1.53	2.18	3.03	4.21	2.98	4.33	4.53	5.99	5.40	6.11
Total Shareholders' Equity	190.97M	275.88M	371.18M	523.34M	375.81M	501.84M	506.7M	679.59M	647.8M	637.99M
Common Stock	115K	117K	120K	122K	127K	131K	133K	136K	140K	141K
Retained Earnings	-193.15M	-117.74M	-23.55M	82.46M	194.97M	296.39M	402.53M	543.74M	643.39M	611.63M
Treasury Stock	0	-23.66M	-62.7M	-75.8M	-410.41M	-456.15M	-635.08M	-696.17M	0	0
Accumulated OCI	-75K	-70K	261K	415K	-227K	-869K	609K	-217K	2.26M	918K
Minority Interest	0	0	0	0	0	0	0	0	0	0

CORT Cash Flow Statement

Corcept Therapeutics Incorporated (CORT) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Cash from Operations	60.94M	115.67M	136.12M	151.97M	167.89M	120.32M	127.04M	198.07M	142M	142M
Operating CF Margin %	38.28%	46.04%	44.41%	42.94%	45.87%	29.94%	26.34%	29.34%	18.65%	-
Operating CF Growth %	231.33%	89.82%	17.68%	11.65%	10.48%	-28.33%	5.58%	55.91%	-28.31%	-481.74%
Net Income	129.12M	75.41M	94.18M	106.01M	112.51M	101.42M	106.14M	141.21M	98.17M	47.9M
Depreciation & Amortization	106K	236K	2.17M	2.24M	3.07M	3.45M	2.36M	1.34M	1.89M	2.03M
Stock-Based Compensation	13.36M	23.75M	29.31M	33.54M	42.93M	42.44M	48.94M	61.35M	84.5M	-21.67M
Deferred Taxes	-76.7M	14.07M	16.88M	14.09M	4.35M	-33.91M	-29.49M	-40.19M	0	-21.76M
Other Non-Cash Items	763K	-1.72M	-1.74M	1.45M	5.09M	1.38M	-9.13M	-10.94M	-15M	18.3M
Working Capital Changes	-5.71M	3.93M	-4.69M	-5.36M	-57K	5.54M	8.22M	45.3M	-27.57M	22.27M
Change in Receivables	-5.44M	-2.29M	-2.34M	-6.27M	-1.43M	-17.43M	-10.07M	1.15M	-5.81M	22.75M
Change in Inventory	-2.26M	-7.78M	-1.04M	-3.51M	3.44M	1.2M	1.26M	305K	-7.48M	-11.36M
Change in Payables	6.29M	-389K	-735K	3.16M	-3.6M	4.76M	5.78M	-2.25M	25.07M	4.5M
Cash from Investing	-73.46M	-90.77M	-117.83M	-119.26M	136.13M	-114.33M	90.91M	-177.6M	69.76M	77.47M
Capital Expenditures	-419K	-298K	-1.09M	-1.24M	-469K	-413K	-139K	-2.17M	-211K	-308K
CapEx % of Revenue	0.26%	0.12%	0.36%	0.35%	0.13%	0.1%	0.03%	0.32%	0.03%	-
Acquisitions	0	0	116.74M	118.03M	-136.59M	0	0	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-73.04M	-90.47M	-116.74M	-118.03M	136.59M	0	0	0	0	0
Cash from Financing	-7.95M	-14.34M	-28.64M	12.21M	-302.59M	-17.28M	-148.72M	-28.35M	-220.37M	-179.8M
Debt Issued (Net)	-15.13M	0	0	0	0	0	0	0	0	0
Equity Issued (Net)	0	-23.66M	-30.98M	-9.95M	-295.99M	0	-145.43M	-6.05M	-245.86M	-164.56M
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	-23.66M	-30.98M	-9.95M	-295.99M	0	-145.43M	-15.66M	-245.86M	-187.78M
Other Financing	7.18M	9.32M	2.33M	22.16M	-6.61M	-17.28M	-3.29M	-22.3M	25.49M	-15.25M
Net Change in Cash	-20.47M▲ 0%	10.56M▲ 151.6%	-10.36M▼ 198.0%	44.92M▲ 533.8%	1.43M▼ 96.8%	-11.29M▼ 891.0%	69.22M▲ 713.2%	-7.89M▼ 111.4%	-7.17M▲ 9.1%	18.92M▲ 0%
Free Cash Flow	60.52M▲ 0%	115.37M▲ 90.6%	135.03M▲ 17.0%	150.73M▲ 11.6%	167.42M▲ 11.1%	119.91M▼ 28.4%	126.9M▲ 5.8%	195.9M▲ 54.4%	141.78M▼ 27.6%	119.79M▲ 0%
FCF Margin %	38.01%	45.92%	44.06%	42.59%	45.75%	29.84%	26.31%	29.02%	18.62%	15.58%
FCF Growth %	232.56%	90.64%	17.04%	11.63%	11.07%	-28.38%	5.83%	54.37%	-27.62%	-32.39%
FCF per Share	0.49	0.91	1.10	1.21	1.33	1.03	1.14	1.73	1.18	1.18
FCF Conversion (FCF/Net Income)	0.47x	1.53x	1.45x	1.43x	1.49x	1.19x	1.20x	1.42x	1.42x	2.50x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	377K	1.35M	6.74M	10.86M	9.1M	39.75M	47.6M	60.27M	0	0

CORT Key Ratios

Corcept Therapeutics Incorporated (CORT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	111.15%	32.31%	29.11%	23.7%	25.03%	23.11%	21.05%	23.56%	15.01%	7.5%
Return on Invested Capital (ROIC)	86.69%	86.02%	40.58%	24.25%	24.95%	22.97%	19.92%	22.09%	6.15%	6.15%
Gross Margin	97.77%	97.92%	98.2%	98.42%	98.56%	98.66%	98.66%	98.39%	98.3%	98.25%
Net Margin	81.11%	30.01%	30.73%	29.96%	30.74%	25.24%	22%	20.7%	13.09%	6.23%
Debt / Equity	-	-	0.01x	0.00x	0.00x	0.00x	0.00x	0.01x	0.01x	0.01x
Interest Coverage	1078.67x	-	-	-	-	-	-	-	-	-
FCF Conversion	0.47x	1.53x	1.45x	1.43x	1.49x	1.19x	1.20x	1.42x	1.42x	2.50x
Revenue Growth	95.77%	57.82%	21.99%	15.46%	3.42%	9.8%	20.04%	39.94%	12.79%	12.2%

CORT SEC Filings & Documents

Corcept Therapeutics Incorporated (CORT) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Apr 30, 2026·SEC

Material company update

Mar 25, 2026·SEC

Material company update

Feb 24, 2026·SEC

10-K Annual Reports

FY 2026

Feb 24, 2026·SEC

FY 2025

Feb 26, 2025·SEC

10-Q Quarterly Reports

FY 2026

Apr 30, 2026·SEC

FY 2025

Nov 4, 2025·SEC

FY 2025

Jul 31, 2025·SEC

CORT Frequently Asked Questions

Corcept Therapeutics Incorporated (CORT) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Corcept Therapeutics Incorporated (CORT) reported $769.1M in revenue for fiscal year 2025.

Corcept Therapeutics Incorporated (CORT) grew revenue by 12.8% over the past year. This is steady growth.

Yes, Corcept Therapeutics Incorporated (CORT) is profitable, generating $47.9M in net income for fiscal year 2025 (13.1% net margin).

Dividend & Returns

Corcept Therapeutics Incorporated (CORT) has a return on equity (ROE) of 15.0%. This is reasonable for most industries.

Corcept Therapeutics Incorporated (CORT) generated $119.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More CORT

Corcept Therapeutics Incorporated (CORT) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Corcept Therapeutics Incorporated(CORT)Earnings, Financials & Key Ratios

CORT Key Insights

✓Strengths

✗Weaknesses

CORT Price & Volume

CORT Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

CORT Recent Earnings

CORT Peer Comparison

Compare CORT vs Peers

vs INVA

vs CVS

Compare Top 5

CORT Income Statement

CORT Balance Sheet

CORT Cash Flow Statement

CORT Key Ratios

CORT SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

CORT Frequently Asked Questions

Explore More CORT

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation